Bayer HealthCare and Onyx Pharmaceuticals have announced that patients treated with Nexavar and capecitabine showed extended progression-free survival during a Phase II trial on advanced metastatic breast cancer.
The study met its primary endpoint of progression-free survival, evaluating Nexavar (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer.
The study showed that median progression-free survival was extended in patients treated with Nexavar and capecitabine, as compared to patients receiving capecitabine and placebo.
The safety and tolerability of the combination did not show any new or unexpected toxicities.
Bayer HealthCare executive committee member and chief medical officer Kemal Malik said that based on these encouraging data, Bayer and Onyx would now evaluate various strategies for Nexavar in breast cancer.
"Nexavar is already benefiting patients worldwide with liver cancer and kidney cancer. Despite significant treatment advances, breast cancer continues to be the leading cause of cancer death in women. We hope to establish Nexavar as an important new treatment option for patients with this devastating disease," Malik said.